Evidence map›Paper›PMID 42015804›Full record

ArticleRenal failure2026

Implementation quality as a modifiable determinant of filter lifespan in regional citrate anticoagulation: a real-world clustering-adjusted study.

Qing Ou, Wenjuan Yan, Zhili Liang, Yanan Liu, Hongbin Hu, Hongjuan Wang, Dan He, Yucheng Li, Hongyun Wei, Zhenhua Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qing OuDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wenjuan YanDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhili LiangDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yanan LiuDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hongbin HuDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hongjuan WangDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Dan HeDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yucheng LiDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hongyun WeiDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhenhua ZengDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Continuous renal replacement therapy (CRRT) is widely used in critically ill patients, but filter clotting remains a common complication. Regional citrate anticoagulation (RCA) is recommended; however, its real-world effectiveness may depend on implementation quality. This single-center retrospective cohort study analyzed 420 CRRT sessions from 1 September 2025 to 30 November 2025. Mixed-effects Cox models with patient-level random intercepts and competing-risk analysis were used. The primary outcome was filter clotting. In adjusted analyses, RCA was associated with a significantly reduced hazard of filter clotting compared with heparin (adjusted hazard ratio (aHR) for heparin vs. RCA: 1.78, 95% confidence interval (CI): 1.14-2.77,

Indexed as

AnticoagulantsCitric AcidContinuous Renal Replacement TherapyAgedBenzamidinesCalciumCritical IllnessFemaleGuanidinesHeparinHumansMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesAnticoagulantsBenzamidinesCalciumCitric AcidGuanidinesHeparinnafamostatcluster analysisContinuous renal replacement therapyfilter lifespanheparinnafamostat mesilateregional citrate anticoagulation

Identifiers

PMID42015804
PMCPMC13103979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.